Form 4: Vaccinex Director Albert Friedberg Increases Stake Through Warrant Exercise and Share Acquisition

Albert Friedberg, a director and 10% owner of Vaccinex, Inc., has increased his holdings through the acquisition of common stock and the exercise of pre-funded warrants.

Summary

• Albert Friedberg, a director and 10% owner of Vaccinex, Inc., has reported a series of transactions that increased his beneficial ownership in the company.
• On November 14, 2024, Mr. Friedberg acquired 30,756 shares of common stock at a price of $3.25 per share.
• Additionally, he acquired 584,646 pre-funded warrants exercisable at $0.0001 per warrant, subject to a 39.99% beneficial ownership limitation.
• These warrants are currently exercisable and will expire upon full exercise.
• The transactions were made through various entities including Pan Atlantic Holdings Ltd., Friedberg Global-Macro Hedge Fund Ltd., and FCMI Parent Co., all of which Mr. Friedberg has a controlling interest in.
• Mr. Friedberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the director's increased stake suggests confidence, but the disclaimer of full beneficial ownership introduces some uncertainty.

Positives

• The acquisition of shares and warrants by a director and significant shareholder signals confidence in the company's future prospects.
• The exercise of warrants at a nominal price of $0.0001 indicates a strong commitment to the company's long-term value.

Risks

• The 39.99% beneficial ownership limitation on the pre-funded warrants could restrict the extent of Mr. Friedberg's potential ownership increase.
• The disclaimer of beneficial ownership, except for pecuniary interest, introduces a layer of complexity in assessing the true extent of Mr. Friedberg's control.

Management Comments

• Mr. Friedberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry where significant ownership stakes are often held by directors and investors.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies, particularly in the biotech sector where large ownership stakes are often held by founders, directors, and early investors.
• The acquisition of shares and warrants by a director is not unusual and is often seen as a positive signal of confidence in the company's prospects.
• The use of pre-funded warrants is a common financing mechanism, allowing investors to acquire shares at a later date at a predetermined price.

Stakeholder Impact

• The increased stake by a director may be viewed positively by shareholders, potentially increasing confidence in the company's future.
• The transactions do not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Vaccinex, Albert Friedberg, Beneficial Ownership, Form 4, Warrants, Share Acquisition, Director, FCMI Parent Co, Pan Atlantic Holdings Ltd, Friedberg Global-Macro Hedge Fund Ltd